News

April 12, 2018 11:30 am
The U.S. Food and Drug Administration (FDA) this week granted Fast Track designation to Karyopharm’s selinexor, an oral Selective Inhibitor of Nuclear Export (SINE) compound for the treatment of myeloma patients who have received at least three...

Pages